PARP1 and hypopharyngeal carcinoma: Our findings from the current study support that Olaparib can significantly inhibit PARP1 expression and consequently sensitize FaDu‐RR cell to radiotherapy, which may help individualize treatment for improved outcomes of patients with hypopharyngeal carcinoma treated with radiotherapy.